Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price Target & Predictions
IRWD Stock Forecast
Ironwood Pharmaceuticals stock forecast is as follows: an average price target of $11.67 (represents a 190.30% upside from IRWD’s last price of $4.02) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
IRWD Price Target
The average price target for Ironwood Pharmaceuticals (IRWD) is $11.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $5.00. This represents a potential 190.30% upside from IRWD's last price of $4.02.
IRWD Analyst Ratings
According to 3 Wall Street analysts, Ironwood Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for IRWD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ironwood Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 09, 2024 | Faisal Khurshid | Leerink Partners | $5.00 | $4.51 | 10.86% | 24.38% |
| Aug 09, 2024 | Mohit Bansal | Wells Fargo | $12.00 | $4.05 | 196.30% | 198.51% |
| May 22, 2024 | David Amsellem | Piper Sandler | $18.00 | $6.82 | 163.93% | 347.76% |
| May 22, 2024 | Mohit Bansal | Wells Fargo | $14.00 | $6.78 | 106.49% | 248.26% |
| Apr 22, 2022 | David Amsellem | Piper Sandler | $16.00 | $12.18 | 31.36% | 298.01% |
The latest Ironwood Pharmaceuticals stock forecast, released on Sep 09, 2024 by Faisal Khurshid from Leerink Partners, set a price target of $5.00, which represents a 10.86% increase from the stock price at the time of the forecast ($4.51), and a 24.38% increase from IRWD last price ($4.02).
Ironwood Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $5.00 | $12.25 |
| Last Closing Price | $4.02 | $4.02 | $4.02 |
| Upside/Downside | -100.00% | 24.38% | 204.73% |
In the current month, the average price target of Ironwood Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ironwood Pharmaceuticals's last price of $4.02. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Aug 09, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 22, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 22, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 16, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 22, 2022 | Piper Sandler | - | Overweight | Initialise |
Ironwood Pharmaceuticals's last stock rating was published by JMP Securities on Oct 01, 2024. The company gave IRWD a "Market Outperform" rating, the same as its previous rate.
Ironwood Pharmaceuticals Financial Forecast
Ironwood Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $117.55M | $113.74M | $107.38M | $104.06M | $107.20M | $108.64M | $97.23M | $97.53M | $117.13M | $103.75M | $104.03M | $88.84M | $116.68M | $103.47M | $89.43M | $79.94M | $126.30M | $131.17M | $102.22M | $68.73M | $69.16M | $52.17M |
| Avg Forecast | $92.60M | $91.23M | $89.17M | $81.90M | $92.48M | $91.22M | $107.10M | $105.75M | $117.47M | $114.00M | $103.70M | $100.35M | $108.04M | $109.15M | $103.55M | $96.62M | $110.17M | $105.28M | $93.85M | $91.15M | $111.95M | $93.10M | $84.76M | $79.34M | $112.03M | $97.16M | $89.29M | $80.56M | $58.95M | $45.19M |
| High Forecast | $95.35M | $93.94M | $91.81M | $81.99M | $94.67M | $91.57M | $107.10M | $108.89M | $118.91M | $116.74M | $106.78M | $103.33M | $111.24M | $109.15M | $103.55M | $96.62M | $110.17M | $105.28M | $93.85M | $91.15M | $111.95M | $93.10M | $84.76M | $79.34M | $112.03M | $97.16M | $89.29M | $80.56M | $70.74M | $54.23M |
| Low Forecast | $90.41M | $89.08M | $87.06M | $81.76M | $89.92M | $90.87M | $107.10M | $103.25M | $116.79M | $112.09M | $101.25M | $97.98M | $105.49M | $109.15M | $103.55M | $96.62M | $110.17M | $105.28M | $93.85M | $91.15M | $111.95M | $93.10M | $84.76M | $79.34M | $112.03M | $97.16M | $89.29M | $80.56M | $47.16M | $36.15M |
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.00% | 1.04% | 1.04% | 0.99% | 1.00% | 0.94% | 1.01% | 1.06% | 0.99% | 1.11% | 0.97% | 1.04% | 1.11% | 1.06% | 1.01% | 1.13% | 1.35% | 1.14% | 0.85% | 1.17% | 1.15% |
Ironwood Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 2 analysts is $105.75M, with a low forecast of $103.25M, and a high forecast of $108.89M. IRWD's average Quarter revenue forecast represents a -10.04% decrease compared to the company's last Quarter revenue of $117.55M (Dec 23).
Ironwood Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $37.59M | $46.46M | $-1.06B | $67.37M | $73.81M | $71.24M | $56.52M | $57.89M | $55.80M | $67.44M | $62.09M | $48.00M | $53.52M | $44.68M | $32.80M | $10.90M | $55.85M | $34.28M | $22.01M | $-48.45M | $-28.61M | $-40.19M |
| Avg Forecast | $14.83M | $14.62M | $14.28M | $13.12M | $14.81M | $14.61M | $17.16M | $84.84M | $18.82M | $18.26M | $16.61M | $77.13M | $69.30M | $51.58M | $48.94M | $70.11M | $52.07M | $49.75M | $44.35M | $41.14M | $52.91M | $44.00M | $40.06M | $13.08M | $52.94M | $45.92M | $42.20M | $-36.00M | $-23.63M | $-33.98M |
| High Forecast | $15.27M | $15.05M | $14.71M | $13.14M | $15.17M | $14.67M | $17.16M | $101.81M | $19.05M | $18.70M | $17.11M | $92.55M | $83.16M | $51.58M | $48.94M | $84.14M | $52.07M | $49.75M | $44.35M | $49.37M | $52.91M | $44.00M | $40.06M | $15.70M | $52.94M | $45.92M | $42.20M | $-28.80M | $-18.90M | $-27.19M |
| Low Forecast | $14.48M | $14.27M | $13.95M | $13.10M | $14.41M | $14.56M | $17.16M | $67.87M | $18.71M | $17.96M | $16.22M | $61.70M | $55.44M | $51.58M | $48.94M | $56.09M | $52.07M | $49.75M | $44.35M | $32.91M | $52.91M | $44.00M | $40.06M | $10.46M | $52.94M | $45.92M | $42.20M | $-43.20M | $-28.36M | $-40.78M |
| Surprise % | - | - | - | - | - | - | - | - | 2.00% | 2.54% | -63.89% | 0.87% | 1.07% | 1.38% | 1.15% | 0.83% | 1.07% | 1.36% | 1.40% | 1.17% | 1.01% | 1.02% | 0.82% | 0.83% | 1.05% | 0.75% | 0.52% | 1.35% | 1.21% | 1.18% |
2 analysts predict IRWD's average Quarter EBITDA for Mar 24 to be $84.84M, with a high of $101.81M and a low of $67.87M. This is 125.70% upper than Ironwood Pharmaceuticals's previous annual EBITDA (Dec 23) of $37.59M.
Ironwood Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $62.47M | $15.32M | $-1.06B | $45.71M | $48.87M | $50.32M | $37.08M | $38.80M | $41.37M | $55.84M | $391.30M | $39.93M | $43.20M | $34.42M | $25.20M | $3.35M | $47.86M | $20.65M | $12.28M | $-59.28M | $-43.14M | $-52.50M |
| Avg Forecast | $8.81M | $9.61M | $4.81M | $4.81M | $8.81M | $11.54M | $24.98M | $55.98M | $32.05M | $32.69M | $39.52M | $50.89M | $51.38M | $42.93M | $52.13M | $46.26M | $44.52M | $48.76M | $35.51M | $34.22M | $45.32M | $21.96M | $13.99M | $4.01M | $34.72M | $16.43M | $-7.95M | $-44.05M | $-35.64M | $-44.39M |
| High Forecast | $9.15M | $9.98M | $4.99M | $6.01M | $9.91M | $11.98M | $24.99M | $67.17M | $62.49M | $51.07M | $41.05M | $61.07M | $61.66M | $42.93M | $52.13M | $55.52M | $44.52M | $48.76M | $35.51M | $41.07M | $45.32M | $21.96M | $13.99M | $4.82M | $34.72M | $16.43M | $-7.95M | $-35.24M | $-28.51M | $-35.52M |
| Low Forecast | $8.54M | $9.32M | $4.66M | $3.61M | $7.71M | $11.18M | $24.97M | $44.78M | $16.02M | $24.51M | $38.31M | $40.71M | $41.11M | $42.93M | $52.13M | $37.01M | $44.52M | $48.76M | $35.51M | $27.38M | $45.32M | $21.96M | $13.99M | $3.21M | $34.72M | $16.43M | $-7.95M | $-52.86M | $-42.77M | $-53.27M |
| Surprise % | - | - | - | - | - | - | - | - | 1.95% | 0.47% | -26.87% | 0.90% | 0.95% | 1.17% | 0.71% | 0.84% | 0.93% | 1.15% | 11.02% | 1.17% | 0.95% | 1.57% | 1.80% | 0.83% | 1.38% | 1.26% | -1.54% | 1.35% | 1.21% | 1.18% |
Ironwood Pharmaceuticals's average Quarter net income forecast for Mar 24 is $55.98M, with a range of $44.78M to $67.17M. IRWD's average Quarter net income forecast represents a -10.39% decrease compared to the company's last Quarter net income of $62.47M (Dec 23).
Ironwood Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $38.67M | $36.05M | $52.48M | $31.12M | $28.39M | $28.62M | $30.12M | $28.86M | $28.69M | $27.74M | $27.05M | $27.65M | $33.98M | $34.93M | $34.64M | $36.45M | $39.19M | $40.92M | $43.25M | $64.74M | $65.40M | $56.02M |
| Avg Forecast | $30.94M | $30.48M | $29.79M | $27.36M | $30.90M | $30.48M | $35.78M | $41.64M | $39.25M | $38.09M | $34.65M | $37.85M | $35.63M | $35.21M | $33.40M | $34.41M | $35.54M | $33.96M | $30.27M | $23.70M | $36.11M | $30.03M | $27.34M | $43.74M | $36.14M | $31.34M | $28.80M | $48.10M | $54.03M | $14.58M |
| High Forecast | $31.86M | $31.39M | $30.68M | $27.40M | $31.63M | $30.59M | $35.78M | $49.97M | $39.73M | $39.01M | $35.68M | $45.42M | $42.75M | $35.21M | $33.40M | $41.29M | $35.54M | $33.96M | $30.27M | $28.44M | $36.11M | $30.03M | $27.34M | $52.49M | $36.14M | $31.34M | $28.80M | $57.72M | $64.83M | $17.49M |
| Low Forecast | $30.21M | $29.76M | $29.09M | $27.32M | $30.04M | $30.36M | $35.78M | $33.31M | $39.02M | $37.45M | $33.83M | $30.28M | $28.50M | $35.21M | $33.40M | $27.53M | $35.54M | $33.96M | $30.27M | $18.96M | $36.11M | $30.03M | $27.34M | $34.99M | $36.14M | $31.34M | $28.80M | $38.48M | $43.22M | $11.66M |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 0.95% | 1.51% | 0.82% | 0.80% | 0.81% | 0.90% | 0.84% | 0.81% | 0.82% | 0.89% | 1.17% | 0.94% | 1.16% | 1.27% | 0.83% | 1.08% | 1.31% | 1.50% | 1.35% | 1.21% | 3.84% |
Ironwood Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $41.64M, based on 2 Wall Street analysts, with a range of $33.31M to $49.97M. The forecast indicates a 7.68% rise compared to IRWD last annual SG&A of $38.67M (Dec 23).
Ironwood Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.01 | $0.10 | $-6.84 | $0.30 | $0.32 | $0.33 | $0.24 | $0.25 | $0.25 | $0.34 | $2.42 | $0.25 | $0.27 | $0.22 | $0.16 | $0.02 | $0.31 | $0.13 | $0.08 | $-0.38 | $-0.29 | $-0.36 |
| Avg Forecast | $0.06 | $0.06 | $0.03 | $0.03 | $0.06 | $0.07 | $0.16 | $0.20 | $0.20 | $0.20 | $0.25 | $0.25 | $0.28 | $0.27 | $0.33 | $0.32 | $0.28 | $0.31 | $0.22 | $0.25 | $0.28 | $0.14 | $0.09 | $0.05 | $0.22 | $0.10 | $-0.05 | $-0.14 | $-0.19 | $-0.17 |
| High Forecast | $0.06 | $0.06 | $0.03 | $0.04 | $0.06 | $0.07 | $0.16 | $0.21 | $0.39 | $0.32 | $0.26 | $0.26 | $0.29 | $0.27 | $0.33 | $0.32 | $0.28 | $0.31 | $0.22 | $0.25 | $0.28 | $0.14 | $0.09 | $0.05 | $0.22 | $0.10 | $-0.05 | $-0.14 | $-0.15 | $-0.14 |
| Low Forecast | $0.05 | $0.06 | $0.03 | $0.02 | $0.05 | $0.07 | $0.16 | $0.20 | $0.10 | $0.15 | $0.24 | $0.24 | $0.27 | $0.27 | $0.33 | $0.32 | $0.28 | $0.31 | $0.22 | $0.25 | $0.28 | $0.14 | $0.09 | $0.05 | $0.22 | $0.10 | $-0.05 | $-0.14 | $-0.23 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | -0.05% | 0.49% | -27.73% | 1.22% | 1.15% | 1.22% | 0.73% | 0.79% | 0.89% | 1.11% | 10.84% | 1.00% | 0.95% | 1.59% | 1.82% | 0.43% | 1.42% | 1.26% | -1.60% | 2.79% | 1.53% | 2.12% |
According to 4 Wall Street analysts, Ironwood Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.20, with a low estimate of $0.10 and a high estimate of $0.39. This represents a 100.00% increase compared to IRWD previous annual EPS of $0.10 (Sep 23).
Ironwood Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $2.15 | $16.00 | 644.19% | Buy |
| ASRT | Assertio | $0.84 | $2.88 | 242.86% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.02 | $11.67 | 190.30% | Buy |
| PCRX | Pacira BioSciences | $16.64 | $35.00 | 110.34% | Hold |
| AVDL | Avadel Pharmaceuticals | $10.72 | $17.80 | 66.04% | Buy |
| AMPH | Amphastar Pharmaceuticals | $44.16 | $66.00 | 49.46% | Buy |
| ANIP | ANI Pharmaceuticals | $55.25 | $79.00 | 42.99% | Buy |
| COLL | Collegium Pharmaceutical | $29.22 | $40.50 | 38.60% | Buy |
| ALKS | Alkermes | $27.55 | $36.38 | 32.05% | Hold |
| NBIX | Neurocrine Biosciences | $117.62 | $147.35 | 25.28% | Buy |
| ITCI | Intra-Cellular Therapies | $82.47 | $94.50 | 14.59% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |